Health Condition 1: C343- Malignant neoplasm of lower lobe,bronchus or lung Health Condition 2: C340- Malignant neoplasm of main bronchus Health Condition 3: C342- Malignant neoplasm of middle lobe,bronchus or lung Health Condition 4: C348- Malignant neoplasm of overlappingsites of bronchus and lung Health Condition 5: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung Health Condition 6: C341- Malignant neoplasm of upper lobe,bronchus or lung
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Intramural Funding, MAHE, Manipal
Eligibility
Inclusion criteria
Inclusion criteria: 1. Non-Small Cell Lung Cancer patients (both males and females) with EGFR positive mutation. 2. Age group of 18-80 years. 3. Patients who are willing to give informed consent.
Exclusion criteria
Exclusion criteria: 1. HIV positive patients. 2. Patients with seriously ill conditions (eg: COVID 19 etc.,) or clinically unstable patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The current research aims to develop an appropriate gefitinib population pharmacokinetic model for deriving an individualized gefitinib dosing strategy for NSCLC patients in tertiary care hospitals.Timepoint: 3 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Development of such a Population pharmacokinetic model for gefitinib will aid in the implementation of precision therapy for the management of NSCLC. Thus, this study would comprehensively analyse precision therapy of lung cancer patients in our settings.Timepoint: 3 years | — |
Countries
India
Contacts
Public ContactMiss Prathvi V Shenoy
Manipal College of Pharmaceutical Sciences, MAHE, Manipal
Outcome results
None listed